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Abstract We have cloned the FP receptor from rat corpus luteum and human uterus cDNA libraries, respectively. The coding DNA sequence in 
the rat cDNA is 1101 bp and is similar to the mouse cDNA coding for a receptor protein of 366 amino acids. The human sequence shows a 5 bp 
deficiency in the 3’ region, truncating the coding sequence to 359 amino acids. Northern blot analysis indicates highest expression in the ovary. Cell 
lines have been established giving stable expression of the FP receptor. Activation of the cloned FP receptor gave an increase in intracellular calcium, 
indicating signaling via phospholipase C-mediated phosphoinositide turnover. Using [%jPGF,, binding of PGs showed the rank order of flupros- 
ten01 > PhXA70 > PGF, 5 PhXA85 > PGD, > PGE,. 
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1. Introduetlon 
Although the presence of specific prostaglandin receptors 
has been recognized pharmacologically [1,2], only recently has 
the cloning of prostaglandin receptors been undertaken. Pro- 
staglandin (PG) receptors are classically defined to be linked 
to the stimulation of second messengers uch as CAMP, IPS or 
intracellular calcium release coupled via a G regulatory protein 
[lo]. The activation of prostaglandin receptors may also result 
in various other responses, including inhibition of adenylyl 
cyclase activity, inhibition of phosphatidylinositol turnover and 
inhibition of Ca*’ mobilization [lO,l 11. The first prostaglandin 
receptor to be cloned was that of thromboxane A,, (TP) [3]. 
Subsequently the receptors for PGE,, the EP,, EP, and EP,, 
have been cloned [3-81. All cloned prostaglandin receptors have 
been of the seven-transmembrane type, coupled to gnanine 
nucleotide binding regulatory (G) proteins linked to either 
adenylate cyclase or the phospholipase C-inositol triphosphate 
pathway (GPCR), which are amongst he most studied receptor 
systems [9]. Recently, distinct PG receptors with identical or 
similar ligand binding specificity have been identified [ 121. Such 
receptors are the isoforms of the EP, receptor [13] which have 
been shown to activate different second messenger systems [14], 
and the TP receptor have recently been shown to exist in at least 
two isoforms [ 151. Thus, it seems that different isoforms of PG 
receptors functionally coupled to different second messenger 
systems exist. While the TP and EP receptors have been cloned 
and characterized there has not until recently been information 
available about the FP receptor [I6181. However, the receptor 
ligand PGF,, has well-known biological effects such as luteoly- 
sis, contraction of the uterus and bronchoconstriction [19,20], 
and this PG may play an important role in a variety of physio- 
logical events. Induction of luteolysis in corpus luteum has been 
shown in a variety of species from rat to man [21,22]. Astrocytes 
have been shown to express FP receptors [23], indicating func- 
tions of PGF, in the central nervous system as well. Agonists 
and antagonists of FP receptors may be important from a 
clinical therapeutic point of view in luteolysis, uterine constric- 
tion, and increasing the blood pressure etc. Prostaglandins, 
especially PGF, and esters of PGF,, have also been shown to 
reduce intraocular pressure [24]. Recently, selective analogues 
of PGF,, with a potential use as anti-glaucoma agents, have 
been identified [25] and may be used to treat glaucoma [26], 
whereas putative drugs which block FP receptors (antagonists) 
may be used therapeutically to treat pathological conditions, 
e.g. in the lungs and uterus. Despite their clinical utility, a 
problem with several currently available FP agonist drugs is 
their many side effects. These side effects are predominantly 
due to a lack of receptor specificity, since several of the FP 
receptor agonists described interact not only with FP receptors 
but with other receptors as well [lo]. 
2. Material and metbods 
2.1. Molecular cloning and sequencing analyses of rat and human FP 
receptors 
*Corresponding author. Fax: (46) (8) 618 8262. 
In order to clone an FP receptor, the polymerase chain reaction 
(PCR) method was used to amplify cDNA sequences from a rat corpus 
luteum cDNA library in the Lambda ZAP11 vector (Stratagene, USA). 
Lambda DNA was prepared as described in [271 and submitted to 45 
cycles of PCR amplification in a total reaction volume of 25 ,ul with 
1 PM each of the following degenerated primers from transmembrane 
regions TM2, 5’ AT1 I(CT)(CG) (TA)I(TC) (TC)TG GCI IT1 ICC 
GAT 3’; and TM7,5’ C(GT)(AG) AA1 AGI AT(AG) TAI ACC CA1 
GGG TC 3’; and 200 PM dNTPs and 2 U Taq DNA polymerase 
(Perkin Elmer-Cetus). The timing used was 45 s (in the first cycle 3 min) 
at 95”C, 3 min at 50°C and 3 min at 72°C. The 72°C step was extended 
with 6 s for each cycle. Individual bands were excised from an agarose 
gel and were submitted separately to 20 cycles of PCR amplification in 
a total reaction volume of 20 ~1 with 100 PM of each of the primers in 
TM2,5’ ATI I(CT)(CG) (TA)I(TC) (TC)TG GCI IT1 ICC GAT 3’; and 
TM7,5’ C(GT)(AG) AA1 AGI AT(AG) TAI ACC CA1 GGG TC 3’; 
200,~M of dNTPs and 2.5 U Taq DNA polymerase, otherwise as in the 
first PCR reaction. PCR fragments were subsequently cloned into the 
PCR II vector using the TA cloning kit (Invitrogen) according to the 
instructions from the manufacturer, transformed into One Shot (In- 
vitrogen) competent cells and the DNA sequenced. One insert was 
found to exhibit close sequence homology to a related receptor. This 
insert was used as a probe to screen a rat corpus luteum cDNA library 
to isolate a full-length clone from the rat corpus luteum cDNA library. 
Positively hybridizing purified phage clones were expanded in E. coli 
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XLl-Blue, and the resulting phage stocks were used to prepare cDNA- 
containing pBluescript plasmids by phagemid excision according to the 
Stratagene protocol. The 4 phagemids with the longest inserts were 
analyzed by DNA sequencing methods. We sequenced our cDNA with 
primers homologous to regions on the Ml3 multiple cloning site ao 
cording to Applied Biosystems protocol for their Taq Dye Deoxy Ter- 
minator cycle sequencing kit. All sequence analysis were performed on 
a Applied Biosysmm Model 373A DNA sequencing system. The gener- 
ated primary data was processed on a VAX computer using the se- 
quence analysis programs from Genetics Computer Group Inc., Mad- 
ison, USA [28].-To-obtain a human probe, &nplification of 350 ng 
human genomic DNA was performed in a 50~1 reaction in 50 mM KCl, 
10 mM Tris-HCl, pH 8.3, 1.5 mM MgC&, 0.1% gelatin, 200 PM each 
of dATP, dCTP, dGTP, dTTP, 2.5 U Taq polymerase (Perkin-Elmer) 
and 3 HIM of the oliaonucleotides 5’-CAC GAC TTG CCA GAC GGA 
GAA’C-3’ and S-T?G TAG AAA CAC CAG GTC CT-3’. An initial 
denaturation step at 94°C followed by 30 cycles of annealing at 55’C 
1 min, extension at 72°C 1 min, denaturation at 94°C 1 min, and tinally 
one cycle of 55’C 1 min, 72°C 10 min. One DNA fragment was ob- 
tained and cloned and sequenced as above; a 80% homology to the rat 
sequence indicated that a fragment of the human fp g&i had been 
found. To isolate a full-length cDNA of the human fD aene. a human 
uterus cDNA gtl 1 library (Clontech) was plated and&<eneh with the 
human probe. Positive plaque pools were picked and subjected to a 
primary and a secondary PCR analysis with nested primers. PCR am- 
plification was performed in a 50 ~1 reaction volume in 50 mM KCl, 
10 mM Tris-HCl, pH 8.3, 1.5 mM MgCl,, 0.01% gelatin and the pres- 
ence of 200 PM each of dATP, dCTP, dGTP, 2.5 U of Taq polymerase 
(Perkin-Elmer) and 30 PM of primer 5’-CAC GAC TTG CCA GAC 
GGA GAA C-3’ and 5’-CCA GTC TIT GAT GTC TTC TGT G-3 
each. Secondary PCR was carried out using 1~1 of the primary PCR 
reaction as template under the same conditions but with the primers 
5’-CAG TAA TCT TCA TGA CAG TGT GG-3’ and 5’.‘ITG TAG 
AAA CAC CAG GTC CT-3. Positive plaque pools were subjected to 
another round of hybridization and PCR amplification until single 
positive plaques could be discriminated. Extracted lambda DNA was 
digested with EcoRI and the DNA fragments were separated on a 0.8% 
agarose gel in lx TAE. Three fragments were purified and ligated into 
pBluescriptSK+. Screening of clones containing inserts was performed 
by restriction enzyme analysis. Positive clones were sequenced as above. 
PCR amplification of the full-length receptor gene for subsequent clon- 
ing into an expression vector was performed using the primers 5’-GTA 
CGT TCT AGA CTC GAG CCA CCA TGT CCA TGA ACA ATT 
CCA AAC AG-3’ and S-ATG CAG GCT TCT AGA TGT CCT ATT 
AAG CTA GGT GCT TGC3’ under the same conditions as ureviouslv 
described. The resulting 1113 bp fragment was cloned into the PCR II 
vector according to the instructions from the manufacturer, trans- 
formed into One Shot (Invitrogen) competent cells and positive clones 
were screened by restriction enzyme analysis with FcoRI. Insert cDNA 
from rat and human was ligated into PCR/CMV (Invitrogen) and 
subsequently sequenced in both directions. 
2.2. Transfections 
A mutant cell line CHO:DG44 (kindly provided by Dr. L. Chasm 
Columbia University) where the dihydrofolate reductase (DFHR) gene 
is deleted was used for transfection. The cells were routinely grown in 
a modified F12 medium (Gibco BRL, Paisly, Scotland) supplemented 
with 5% bovine serum (HyClone Laboratories Inc., USA). Cells wer 
transfected by the CaPO, precipitate method [30,31] with the above- 
mentioned rat and human vector constructs, and co-transfected with 
the DHFR gene in a ratio of 10: 1, respectively. Transformants positive 
for DHFR were selected in a F12 medium lacking hypoxantine, glycine, 
thymidine (Gibco BRL), supplemented with 10% dialyzed fetal bovine 
serum (HyClone Lab Inc.). Methotrexate (Sigma Chemical Co, USA) 
was used to amplify the transfected genes. 
2.3. Flow cytometry 
To tind high expressing clones, flow cytometry analysis was per- 
formed on rat FP-transfected CHO cells, amplified with 20 nM MTX 
and 100 nM, respectively. The antibodies used in the analysis were 
biotinylated rabbit anti-FP carboxy-tetminal IgG (Pharmacia Bio- 
Science). Cells in PBS at a density of lo7 cells/ml were incubated at 22O C 
in a concentration of 13 pug antibody/ml for 30 min. For detection, 
fluoresce&conjugated avidin (Molecular Probes A-2662) was used. 
Cells stained with avidin only were used as a negative control. Flow 
cytometryc analysis was performed using an EPICS 753(Coulter Elec- 
tronics, Hialeah, FL). 
2.4. Northern blot analysis 
Nylon membranes blotted with 2pg poly(A)+ RNA from eight differ- 
ent rat tissues (heart, brain, spleen, lung, liver, skeletal muscle and 
testis) and eight human tissues (spleen, thymus, prostate, testis, ovary, 
small intestine, colon and peripheral blood leukocytes (MTN-Blot, 
Clontech) were used for analysis. The rat blots were probed with a rat 
fi fragment and the human blot with a humanfp fragment according 
to the protocol for QUIKHYB (Stratagene) and analyzed in a 
PhosphorImager (Molecular Dynamics). 
2.5. Ligand binding 
All steps were carried out at + 4°C. Cells were washed once with PBS 
and then scraped from roller bottles into cold PBS and spun down. The 
cells were homogenized using a glas homogenisator (Dounce) and cen- 
trifuged. The supernatant was then centrifuged at 100,000 x g for 60 
min using a Beckman ultracentrifuge, and the tinal pellet was suspended 
in 50 mM Tris-HCl, pH 7.0, with 2.5 mM MnCl,. Protein concentration 
was determined by the method of Lowry [32]. Cell membranes (1OOpg) 
were incubated with [‘H]PGF, (specific activity 154 Cilmmol; New 
England Nuclear) in 50 mM Tris-HCl, pH 5.8, containing 2.5 mM 
MnCl, in a total volume of 0.2 ml for 60 min at room temperature. After 
incubation the samples were filtered through GF filters (particle reten- 
tion size of 1 .O pm) using a Skatron cell harvester. Specitic binding was 
calculated by subtracting the values for non-specific binding in the 
presence of 10e5 M unlabelled PGF&. All samples were assayed in 
triplicate. In saturation analysis (‘hot’ Scatchard plot) concentrations 
of 0.5-15 nM of PHJPGF, were used. For competitive binding, cell 
membranes were incubated with 3 nM rI-IJPGFz, together with varying 
concentrations (5 x lo-l3 to 10v5 M) of different m&belled ligands 
(prostaglandins F,, E,, Dz , fluprostenol, PhXA70 (l’l-phenyl- 
18,19,20-trinor-PGFA and PhXA85 (13,14-d&y&o-17-phenyl- 
18,19,20-trinor-PGF& [25]). Ligand binding experiments with CHO 
cells expressing the human FP receptor were carried out witb intact cells 
cultured in 96Iwell plates at a density of 10,000 cells/well, incubated 
with I’I-IlPGF,, (0.5-10 nM) in 50 mM Tris-HCl. pH 5.8, containing 
2.5 mM MnClTm a total volume of 0.2 ml for 45 min at room temper- 
ature. The cells were lysed by adding NaOH to each well and the lysed 
cells were transferred to scintillation vials, mixed with scintillation 
cocktail (Ultima Gold; Packard) and counted. Non-specific binding 
was determined in the presence of lo-’ M unlabelled PGF,. Data were 
analyzed using the EBDA/LIGAND program [33]. Data were fitted to 
sinale and multiule site models and comnared for statistically signiticant 
di&rences. The high and low afiinity l&ling sites were designated as 
RH and RL and their corresponding a.Binity constants as KH and KL, 
respectively. The concentration (IC,) of each ligand to cause 50% 
inhibition of the binding of 13HlPGF,fl was derived from binding curves. 
EBDA was used to pe;fo&~ &at&&d analysis for determination of 
maximum number of bindine sites (B_..j and dissociation constant (&) 
for PH]PGF,. 
2.6. Functional analysis 
An analysis of the functional activation of the cellular signal 
transduction was performed as an activation of intracellular calcium 
responses in a spectrofluorometer (PTI, USA, data not shown). CAMP 
analysis gave, as expected, no altered levels in PGF,-challenged cells. 
The functionality was tested in a microphysiometer as well (Cytosensor; 
Molecular Devices, USA). Activation of second messenger systems 
have been shown to change the extracellular pH around cells due to an 
increased metabolism [34]. 
3. Results and discus&on 
3.1. Isolation and characterization of full-length cDNA clones 
for a Fza receptor: cloning and sequencing analyses of F2. 
receptor cDNA 
In order to clone the FP receptor, a PCR method was used 
to selectively amplify cDNA sequences from a rat corpus 
luteum cDNA library. Ovine and bovine corpus luteum has 
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previously been shown to express this receptor subtype [12,36]. 
PCR amplification was performed with pairs of highly degener- 
ated primers derived from the second and seventh, and third 
and sixth, transmembrane regions, respectively, of previously 
cloned seven-transmembrane r ceptor super family members 
and in particular the TP receptor. This process resulted in the 
amplification of several cDNA fragments. 
The amplified cDNA fragments were preliminarily charac- 
terized by DNA sequence analysis. One of the cDNA fragments 
was found to exhibit considerable sequence homology to the 
previously cloned G protein-coupled TP receptor and was sub- 
sequently used to screen the rat corpus luteum cDNA library 
in order to isolate a full-length clone. TXventy-four cDNA 
clones with insert sixes ranging from about 1.7 to 3.3 kb were 
isolated, all of which strongly hybridized with the 32P-labeled 
PCR probe on southern analysis (data not shown). One of these 
clones, with an insert of about 3 kb, was sequenced and found 
to exhibit more than 55% amino acid sequence homology to 
1 
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ATGTCCATAAACAGTTCCAAGCAGCCGGCGTCCTCTGCAGCTGGACTCATCGCCAACACG 
_________+__--___-_+--__---~~+---~~~-~~+~~-~~~-~~~-~~--~~_-+ 60 
TACAGGTATTTGTCAAGGTTCGTCGGCCGCAGGAGACGTCGACCTGAGTAGCGGTTGTGC 
* * 
MSINSSKQPASSAAGLIANT 20 
U-tensinus 
ACTTGCCAGACGGAGAACCGCTTTCAGTGTTCTTTTCAAG 
-___--___+___--__--+__-______+-_______-+___-__-__+-_~~-~~~-+I2O 
TGAACGGTCTGCCTCTTGGCCGAAAGTCACAAGAAAAGTTATTAGAAGTACTGCCACCCC 
1 
TCQTENRLSVFFSIIFMTVG 40 
TN-1 
ATTGTATCTAACAGCCTGGCCATTGCCATCCTCATGAAGGCGG 
_--__--__+-___--___+__--__--_+_-_______+_________+_____-___+I8O 
TAACATAGATTGTCGGACCGGTAACGGTAGGAGTACTTCCTCTGCC 
JVSNSLAIAILMKAY ,RFR*fi 60 
IC-1 
AAGTCGAAGGCTTCTTTCCTGCTCTTGGCTAGTGGCCTGGTTCTTCGGC 
_________+_________+_________+_________+_________+_________+240 
TTCAGCTTCCGAAGAAAGGAG~CCGATCACCGGACCACTAGTGTCTG~G~~CG 
2 
KSKASFLLLASGLVITDFFG 80 
TM-2 
CACCTCATCAACGGAGGGATAGCTGTCTTCGTCTTCGTATAC~TTCTGAT~GACT~ATCCGC 
__--__--_+_________+__-____-_+_-___-___+___-___-_+-___--__-+3OO 
GTGGAGTAGTTGCCTCCCTATCGACAGAAGCATATGCATATGCG~GACTATTTCTGACCTA~CG 
H L IN GG I AVF VYA S D KD W I RlOO 
EC-1 
TTCGATCAATCGkACATCCTGTGCAGTGTTTTTGGGATCTTGTTCTCTGGCTTG 
______--_+--~~--_--+_--__---_+-~~--~~--+~~~~~~~_~+~~~~~~~~~+36O 
AAGCTAGTTAGCTTGTAGGACACGTCACAAAAACCCCTAGAGGTACCAC~GAGACCG~C 
1 
FD Q S N I LCS VF G I SMVF S G L 120 
Tn-3 
TGCCCACTTTTCCTGGGCAGTACGATGGCCATTGAGAGGTCCCT 
_-___-___+-___-__--+_-_______+--_____-_+___-__--_~_-__--__-~42O 
ACGGGTGAAAAGGACCCGTCATGCTACCGGTACC~T~CTCTCCACGTAGCCCCAGT~TT~GA 
.C P L F L G S TMA I ER CI G VTNP140 
IC-2 
CTATTCCACTCTACAAAGATCACGTCTAAGCATGTGTG~TGATACTGAGC~TGTGTGC 
--__--__-+ __-______+___-___--+__-_---__+__-__--__+-__--__-_~48O 
GATAAGGTGAGATGTTTCTAGTGCAGATTCGTACACTTTTACTATGACTCGCCACACACG 
3 3 
LFHS TKI TSK H VKM I L S G VC 160 
!R4-4 
ATGTTTGcTGTCTTCGtGGcCCTGTTGcCCATCCTTGGAC 
-_---_--_+--___-__-+_________+_____--__+-_____--_+_-__--_--+54O 
TACAAACgACAGAAGCaCCgGGACAACgGGTAGGAACCTGTGGCTCTAATAGTTTAGGTT 
IF AVF VA L L P I L GH RR Y Q I Q180 
EC-2 
GCATCCAGAACTTGGTGCTTCTACAACACACACATCGGTTC 
-_-se_-mm+__-______+__--__-__+-__ ~~~_~~+-~~--~~--+~--~~~-~~+6OO 
CGTAGGTCTTGAACCACGAAGATGTTGTGTCTCGTGTAGC 
1 
AS RT WC F YN T E H I ED WEDRF 200 
m-5 
Fig. 1. The nucleotide sequence of a FP receptor along with the deduced amino acid sequence of the longest open reading frame. The nucleotide 
sequence is numbered from the putative initiator methionine and indicated at the left of each line, while the amino acid numbers are indicated at 
the right of each line. Transmenbrane regions are indicated by heavy lines, intracellular regions are in italics and extracellular regions are in normal 
font. Consensus sites are indicated as follows: *, N-glycosylation; 1, disulphide bond; 2, PKA phosphorylation; 3, PKC phosphorylation; and 4, 
cysteine myristylation. 
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TATCTCTTGTtCTTttCTTCCCtGGGACTCTCTTAGcTCGc 
__-_--__-+_________+ _________+__-______+_--__-__-+__-____-_+66O 
ATAGAGAACAaGAAaaGAAGGGaCCCCTGAG~TCgAGACgTAGAGT~GA~ACGTTg 
Y L L F F S S L G L L A L G I S F SC N 220 
GcCGtCAcGGGAGTCACACTTTTGAGAGTGAAGTTTAGAA 
______-__ +_________+_________+__--___--+_-___---+_--___--_+72O 
CgGCaGTgCCCTCAGTGTGAAAACTCTCTCACTTC~TCTTCAGTCGTCGTGTCCGTTCCG 
AV T G"TLLR*"KFRSQQHRQG240 
IC-3 
AGGTCCCACCACCTGGAGATGGTCATTCAGCTCCTGGCCAT~TGTGTGTCTCCTGCGTC 
__--_--_-+_________ +~~-~~~-~-+--~~~-~-~+~-~---~~-+_~~~--~--+78O 
TCCAGGGTGGTGGACCTCTACCAGTAAGTCGAGGACCGAGGACCGGTATTACACACAGAGGACGCAG 
RSHHLEMVIDLLAIMCVSCV 260 
TM-6 
TGCTGGAGTCCCTTTCTGGTGACGATGGCCAACATTGCAATTCCCCA 
________-+___-~-_-~+_-~---_~-+_~---~___+~---~__-~+--~~-_~~-+84O 
ACGACCTCAGGGAAAGACCACTGCTACCGGTTGTAACGTTGGGT 
CWSPFLVTMANIA I N G N* N S P 280 
EC-3 
GTGACCTGTGAGACGACGCTCTTTGCTCTCCGAATGGCAA 
___-_-_--+_______-_+___--____+___-__--_+_____-___+_________+gOO 
CACTGGACACTCTGCTGCGAGAAACGAGAGAG~TTACCGTTGGACCTT~TCTAT~TCTG 
1 
VT CF, T T LF ALRMATWN 0 I LD 300 
p WVY I L L B KA VL RNL YKLA S 320 
C-tenuinua 
CGCTgCTGTGGAGTGAACATCATCAGCTTGCACATCTGGGT 
_________+__--_-___+-__--___-+__-______+________~+__~~__~~_+~~~ 
GCGAcGACACCTCACTTGTAGTAGTCGAACGTGTGTAGACCCTTGAGTCGAGGTAGTTCTTA 
4 4 3 
R CCG VNI I SLH I WEL S S IKN340 
TCCTTAAAGGTTGCTGCTATCTCTGAGTCACCGGCTGCAG 
________-+__-__--__+___-_____+_________+___ --_---+----_----+~O8 
AGGAATTTCCAACGACGATAGAGACTCAGTGGCCGACGACGTCTCTTCCTCTTAGTcGTTCGT 
S3LKVAAISESPAAEKENQQA360 
TCTAGTGAGGcTGGACTGTA 
__--__--_+-________+_ 1101 
AGATCACTCCgACCTGACATT 
SSEAGL* 366 
Fig. 1. (continued). 
related PG receptors in the coding regions of the sequence. The 
nucleotide and deduced amino acid sequence for the cloned FP 
receptor is shown in Fig. 1. The longest open reading frame in 
this cDNA codes for a 366 residue protein with a theoretical 
molecular weight of 41 kDa. Putative glycosylation as well as 
other post-translational modifications may increase the molec- 
ular weight. Although there are neighboring sequences with 
ATG in the reading frame similar to Kozak’s consensus initia- 
tion sequence [37], the Met codon at position 1 provides the 
most probable initiation site (Fig. 1). A Kyte and Dolittle hydro- 
phobicity analysis of the translated protein reveals seven clus- 
ters of about 25 hydrophobic residues, predicted to represent 
transmembrane-spanning domains, connected by three ex- 
tracellular and three intracellular loops. This pattern is similar 
to that observed for other cloned G protein-coupled receptors 
where the amino-terminus is proposed to be extracellular and 
the carboxy-terminus projects into the cytoplasm [38]. 
The human FP receptor cDNA was identified and cloned 
from a human uterus cDNA library using a human probe 
obtained with rat-specific PCR primers. Homology analysis 
showed homology with the published sequence for the human 
FP receptor [17] except in positions 63 and 213 where cytosine 
to thymidine substitutions were shown. However, these base 
substitutions do not give rise to any amino acid substitutions, 
Comparison between mouse and rat FP cDNA sequences how 
83.5% and 80.5% homology, respectively (Table 1). It is inter- 
esting to note a 5 bp deletion in the 3’ end of the human 
sequence compared to the mouse and rat sequences, giving a 
Table 1 
Percent identity and similarity between the FP receptor in man, rat and 
mouse. 
Mouse 
Rat 
Rat 
Id 95.6% 
Sim 97.5% 
Human 
86.7% 
93.6% 
85.6% 
93.1% 
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Mus 1 
Hum 1 
Rat 1 
MUS 51 
Hum 51 
Rat 51 
Mus 101 
Hum 101 
Rat 101 
Mus 151 
Hum 151 
Rat 151 
Mus 201 
Hum 201 
Rat 201 
Mus 251 
Hum 251 
Rat 251 
Mus 301 
Hum 301 
Rat 301 
MUS 351 
Hum 351 
Rat 351 
MSMNSSKOPVSPAAGLIANTTCQTENRLSVFFSIIFMTVGILSNSLAIAI 
IIII.iIT IIll :I:. IIIlTllllllllll:lIllllllllllllll 
MSMNNSKQLVSPAXALLSNTTCQTENRLSVFFSVIFMTVGILSNSLAIAI 
Il:l.IlI .I.I :I:.IIIIIIIIiIIIIII:lIlIlII:IlIIiIII 
MSINSSKQPASSAAGLIANTTCQTENRLSVFFSIIFMTVGIVSNSLAIAI 
TMI------------_--_- 
LMKAYQRFRQKSKASFLLLASGLVITDFFGHLINGGIAVFVYASDKDWIR 
lllll~lllrlllllllllllllllllllllllll:llllllllll:lll 
LMKAYQRFRQKSKASFLLLASGLVITDFFGHLINGAIAVFVYASDKEWIR 
IIIIIIIII.IIIIlIIIIIIIIIIIIIllIIIII:IIIIIIIIII:III 
LMKAYQRFRRKSKASFLLLASGLVITDFFGHLINGGIAVFVYASDKDWIR 
FDOSNILCSILGISMVFSGLCPLFLGSAMAIERCIGVTNPIFHSTKITSK 
llTll:llll:ll:lllllIlll:lll.llllllllIl.lllllllllll 
FDQSNVLCSIFGICMVFSGLCPLLLGSVMAIERCIGVTKPIFHSTKITSK 
IIIII:III:III:IIIIIIIII:III.IIIIIIIIII.l:IIIIIILII 
FDQSNILCSVFGISMVFSGLCPLFLGSTMAIERCIGVTNPLFHSTKITSK 
TM3-__------------_-_-- 
HVKMILSGVCMFAVFVAVLPILGHRDYQIQASRTWCFYNTEHIEDWEDRF 
IIII:IIIII:IIII:I:IIIIIIIII.IIIIIIIIIIlll.I.IIIIII 
HVKMMLSGVCLFAVFIALLPILGHRDYKIQASRTWCFYNTEDIKDWEDRF 
IIIl:IIIll:lIII:IIIIIIIlIlI.IIIIIIlIIIlIl.I.IIlIIl 
HVKMILSGVCMFAVFVALLPILGHRDYQIQASRTWCFYNTEHIEDWEDRF 
TM~~_~~_-~~_~~~-~~~~-~-~ TM 
YLLFFSFLGLLALGVSFSCNAVTGVTLLRVKFRSQQHRQGRSHHLEMIIQ 
III:IIIIIIIIIIII: III:II:IIIIIII:IIIIlIIIIIIIII:II 
YLLLFSFLGLLALGVSLLCNAITGITLLRVKFKSQQHRQGRSHHLEMVIQ 
IIl:II IIIIIIl:l: III:II:IIIIIII:IIIIIIIIIIIIIIIII 
YLLFFSSLGLLALGISFSCNAVTGVTLLRVKFRSQQHRQGRSHHLEMVIQ 
5______-__-___-__-___-_ T 
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LLAIMCVSCIWWSPFLVTMANIGINGNHSLETCETTLFALRMATWNQILD 
IIIIIIIIl: IIlIlIlIIIl:IIII:I IIIIlIIIIIIlIIIlIII 
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IIIIIIIIIIII:IIIIIII.IIII::IIIIIIIIIIIIIIIIIII.III 
PWVYILLRKAVLKNLYKLASQCCGVHVISLHIWELSSIKNSLKVAAISES 
lIIIIIlIIIIl:IlIIIII.llII::IIlllllIIIIIIllIIIIlIII 
PWVYILLRKAVLRNLYKLASRCCGVNIISLHIWHLSSIKNSLKVAAISES 
PAAEKESQQASSEAGL 366 
1.111.. 
PVAEKSAST....... 359 
1.111.. 
PAAEKENQQASSEAGL 366 
50 
50 
50 
100 
100 
100 
150 
150 
150 
200 
200 
200 
250 
250 
250 
Fig. 2. Comparison between the FP receptor amino acid sequences in mouse, man and rat. 
translational frame shift and truncating the carboxy-terminus 
in the human amino acid sequence (Fig. 2). 
3.2. Characterization of the amino acid sequences for the rat FP 
receptor clone 
Comparison of the deduced amino acid sequence for the 
cDNA clones with the sequences of various rodent prosta- 
glandin receptors is shown in Fig. 3. As can be seen, the regions 
of highest identity appear to occur within the predicted trans- 
membrane-spanning domains. Within these regions, the FP 
protein exhibits the highest sequence homologies with the 
mouse EP1 and TP receptor. The amino- and carboxy-termini 
and the extracellular and intracellular loops are significantly 
more divergent among these receptors. 
The long carboxy-terminus contains several serine residues, 
possibly representing additional sites for regulatory phospho- 
rylation. The amino acid sequence reveals, by a theoretical 
analysis, the following: two possible N-glycosylation sites are 
located in the amino-terminus and one in the third extracellular 
(EC) loop. Four cysteines are located in the putative extracellu- 
lar parts, giving the possibility for two disulfide bonds. Except 
for the Cys-Cys bond found in most, if not all, GPCR, in EC-l 
and EC-2, FP also has another possible pair in the amino- 
terminus and the EC-3, a feature shared by the EP, but not 
other PG receptors. Other GPCR’s having similar located cys- 
teines seem to belong to the small peptide-ligand receptor fam- 
ily, e.g. the IL-8 receptor. 
Consensus recognition sites for phosphorylation of protein 
kinases of both the PKC and PKA type are found in the intra- 
cellular (IC) loops and the carboxy-terminus; all together there 
are seven Ser and Thr residues as possible sites. These 
phosphorylations are proposed for the regulation of transmem- 
brane signaling and desensitization of the receptor [39]. Proba- 
ble Cys myristylation site(s) are located in the carboxy-termi- 
nus. EP, and EP, also have Cys in similar positions. These 
myristylatitions give a fourth intracellular loop which may in- 
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Fig. 3. Comparison of the rat FP receptor amino acid sequence with that of other known orostaelandm recenters. Amino acid sequences of the mouse 
TP receptor, the mouse EP,, EP, and EP, receptor were aligned to 
transmkbrane (TM) region; are indicated by the intermittent &es. 
optimize the domolc&y with a ;at FP receptor seq&nce. The putative 
teract with G proteins [40] and affect the phosphorylation of and TP) and EP, and EP2. The C-terminus of the EPI is consid- 
the carboxy-terminus [41]. A major difference in size of the erably longer than that of the FP and of the rest of the PG 
third IC loop is observed between FP (together with the EP, receptors. 
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Fig. 4. Northern blot, rat. Lane 1, heart; 2, brain; 3, spleen; 4, lung; 
5, liver; 6, skeletal muscle; 7, kidney; 8, testis. The lower diagram shows 
a densiometric analysis of the 6 kb band and the relative xpression of
it in the presented tissues. 
The similarity between FP and any PG receptor in the TM 
regions vary from about 45% in TM4 and TM5 to 76% in TM6 
and TM7, the identity, i.e. the same aa in the same position vary 
from 4% in TM5 to 44% in TM7. The 16 aa most adjacent to 
the cytoplasm in TM7 are almost all identical, 10/16, an out- 
standing hallmark of the PG receptors. As pointed out by 
Hirata earlier [3], the Arg in TM7, conserved in all prostanoid 
receptors, may reflect the binding site of the acidic group in 
substances uch as the prostaglandins [3,42,43]. It is interesting 
to note that within the third putative transmembrane domain 
of FP, as well as in the other PG receptors, there is not a 
conserved aspartate residue which is common to all biogenic 
amine receptors that have been sequenced thus far. Moreover, 
the fifth transmembrane-spanning domain of FP also contains 
two serine residues conserved among catecholamine receptors 
and critical for the recognition of agonist ligands possessing a 
catechol group [44]. Other PG receptors except EP, lacks these 
serines. 
3.3. Northern analysis 
A common transcript at about 6 kb was shown in all rat 
tissue (Fig. 4). Heart, brain and skeletal muscle showed addi- 
tional transcripts of lower size, ranging from 2 to 6 kb. Highest 
expression was found in brain followed by lung and skeletal 
muscle. Heart, spleen, liver and testis all expressed the tran- 
script while the kidney showed no detectable xpression. The 
pattern in brain and skeletal muscle were similar. The variation 
of expression pattern, as shown in our rat tissue blot, differs 
Table 2 
rH]PGF, and [3H]PhXA85 saturation binding characteristics in mem- 
brane preparations of CHO cells expressing the transfected rat FP 
receptor. 
Ligand I(d (nM) B, (fmol/mg protein) 
PC&, 8.3 f 2.5 78 + 23 
PhXA85 18.5 + 0.1 158 f 18 
Data are mean If: SE of 3 independent experiments 
from previously published thromboxane and prostaglandin E 
receptors both in the size of transcript and the multiplicity of 
transcripts in the tissues of heart, brain and muscle. The possi- 
bility that subtypes of the FP receptor exist can not be ruled 
out since a cross-hybridization with other PG receptors seem 
unlikely according to the published sixes of major PG receptor 
transcripts in mice. A study of the various sized bands in rat 
tissues has currently started. The human tissues examined did 
not show the size variability in transcripts found in rat (Fig. 5). 
A major transcript of about 6 kb was found in all tissues 
expressing the FP receptor, with the highest expression in the 
ovary followed by the small intestine, prostate, spleen and tes- 
tis. Weak expression was shown in the colon and thymus but 
no expression was detectable in leukocytes. In tissues with a 
high expression, a minor transcript of a larger size of 6.5 kb 
could be detected. These different mRNA expression dam may 
indicate a species difference in putative subtypes of the FP 
receptor. 
3.4. Ligand binding 
Ligand binding with radiolabeled [3HJPGF, and competi- 
tion with other prostaglandins on membranes prepared from 
the transfected cells is one way of confirming the identity of the 
cloned cDNA. Scatchard analysis showed a specific [3H]PGF, 
binding to these membranes with a K,, value of 8.3 k 2.5 nM 
6 kb 
12 3456 7 8 
Fig. 5. Northern blot, human. Lane 1, spleen; 2, thymus; 3, prostate; 
4, testis; 5, ovary; 6, small intestine; 7, colon; 8, leukocyte. Otherwise 
as Fig 4. 
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Fig. 6. Microphysiometer analysis of CHO cells expressing the transfected rat FP receptor (series 2) and untransfected CHO cells (series 1). 
Prostaglandins D2 and F, are tested in this experiment by challenging the cells in the two treatment periods, respectively. % change in -pV/s on 
the x-axis and time in seconds after the start of the microphysiometer on the y-axis. 
and a B,, of 78 + 23 fmol/mg protein (Table 2). The rank order 
of potency of prostaglandins competing for [‘H]PGF,-specific 
binding at the FP receptor was fluprostenol > PhXA70 
> PGFza z PhXA85 > PGDZ > PGEZ (Table 3). A two-site 
model gave the best fit with the two ligands PGF, and flupros- 
tenol; PhXA85 and the other gave best fit with a one-site model 
(for Ki, I&, and B_ values see Table 4). These values are in 
agreement with published values of tissue preparations express- 
ing the FP receptor. Comparing these ligand binding data with 
the ones presented for the cloned mouse and human FP recep- 
tors [16,171, there is a difference in the binding of PGDZ to the 
rat and mouse FP receptor compared to the human receptor. 
The binding of PGDz and PGFza to the human FP receptor 
does not differ significantly, while in the rat and mouse there 
is a difference in binding of 10-100 times between PGDz and 
PGFti 
FP-expressing CHO cell line with various PGs (Fig. 6). These 
observations uggest hat our rat cDNA clone encodes an en- 
dogenous prostaglandin Fza receptor and that we have a func- 
tional response in our transfected rat FP-expressing CHO cells. 
A major goal of clinical pharmacology and the pharmaceuti- 
cal industry is the development of more selective drugs with 
greater efficacy than those currently in use. Impediments for 
such a process regarding targeting of the FP receptor are the 
low abundance of the receptor protein available to study in 
tissue, and the lack of suitable homogeneous model systems of 
the receptors with which to screen drugs. Commonly cells used 
for PGFza receptor analysis are obtained from bovine corpus 
luteum preparations, which also contain EP receptors [35]. 
Untransfected CHO cells as well as FP receptor transfected 
cells were stimulated with prostaglandins. The PGF, stimula- 
tions gave alterations in pH around the transfected CHO cells 
but not in the untransfected host CHO cells. Stimulations with 
PGD2 gave no response in any of the two cell lines (Fig. 6). The 
functional analysis of the FP receptor-expressing CHO cells 
showed a coupling to PLC and an activation of intracellular 
calcium as expected (data not shown). It was also possible to 
analyze physiological responses when challenging the stable 
A novel approach to the solution of this problem is to clone 
cDNAs encoding FP receptors, construct expression vectors 
containing these cDNAs, and create a series of stable trans- 
fected mammalian cell lines or prokaryotic cells which express 
functional FP receptors in abundance. These cell lines, which 
would express a homogeneous population of FP receptors, can 
be used by the pharmaceutical industry or others to screen 
drugs and study the FP receptors using a variety of biochemi- 
cal, physiological and pharmacological techniques. To accom- 
plish this goal, we have isolated the cDNA encoding a rat 
FP receptor linked to the activation of second messengers as 
measured by intracellular calcium. This cDNA was inserted 
Table 3 
Binding parameters of prostanoid agonists to membranes prepared from CHO cells expressing the transfected rat FP receptor. 
L&and K (nM) 1% (nW B,, (fmopmg) Two site model* 
Ku (nM) Kr. (nM) RH (8) 
PGF,, 11 f2 18 f 3 146 f 4 3.9 f 1.6 34f 10 55 f 8 
PGE2 400 f 100 660 + 170 153f8 
PGDl 470 + 170 800 f 254 184 f 18 
PhXA 85 11 f2 18 +4 136f 11 
PhXA 70 1.1 f 0.2 1.7 f 0.3 48 + 2 
Fluprostenol 0.4 f 0.1 7.5 + 1.5 114f3 0.2 r 0.9 225 10 65 + 3 
Data are means k SE from 3-4 independent experiments 
Ku and K, = affinity constants for high and low binding sites 
R, and R, = proportion of high and low aftinity binding sites 
*The two-site fit is signiticant better (P > 0.05) than the single site analysis 
R, (8) 
45 + 8 
35 f 3 
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Kakizuka, A., Ito, S., Ichikawa, A. and Narumiya, S. (1993) Na- 
ture 365, 166-70. 
Table 4 
X;, values for [31-QPGFzcl specific FP receptor binding to intact CHO 
cells expressing the rat and human FP receptor, respectively. 
Receptor Kd (nM) n 
Rat 2.25 * 0.34 4 
Human 1.63 f 0.39 3 
mean values + SE 
into different eukaryotic expression vectors and used in the 
construction of cell lines expressing a functional protein. The 
resulting FP receptor-expressing cell lines were used to investi- 
gate the affinity and efficacies of agonist and putative antago- 
nist drugs of a FP receptor using various techniques, such as 
radioligand binding and in mammalian cell line second messen- 
ger assays. 
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